Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi FS, Dranoff G, Wucherpfennig KW.

Science. 2018 Mar 30;359(6383):1537-1542. doi: 10.1126/science.aao0505.


Postcode lotteries in public health--the NHS Health Checks Programme in North West London.

Graley CE, May KF, McCoy DC.

BMC Public Health. 2011 Sep 28;11:738. doi: 10.1186/1471-2458-11-738.


Prostate cancer immunotherapy.

May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW.

Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23.


Ex vivo characterization and isolation of rare memory B cells with antigen tetramers.

Franz B, May KF Jr, Dranoff G, Wucherpfennig K.

Blood. 2011 Jul 14;118(2):348-57. doi: 10.1182/blood-2011-03-341917. Epub 2011 May 6.


B7-deficient autoreactive T cells are highly susceptible to suppression by CD4(+)CD25(+) regulatory T cells.

May KF Jr, Chang X, Zhang H, Lute KD, Zhou P, Kocak E, Zheng P, Liu Y.

J Immunol. 2007 Feb 1;178(3):1542-52.


Immune competence of cancer-reactive T cells generated de novo in adult tumor-bearing mice.

May KF Jr, Lute K, Kocak E, Abdessalam S, Yin L, Li O, Guan Z, Philips G, Zheng P, Liu Y.

Blood. 2007 Jan 1;109(1):253-8. Epub 2006 Aug 8.


Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.

Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, Abdessalam SF, Lehman AM, Jarjoura D, Zheng P, Liu Y.

Cancer Res. 2006 Jul 15;66(14):7276-84.


Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.

Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P, Liu Y.

Blood. 2005 Nov 1;106(9):3127-33. Epub 2005 Jul 21.


Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.

Roychowdhury S, May KF Jr, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA.

Cancer Res. 2004 Nov 1;64(21):8062-7.


Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies.

May KF Jr, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, Ferketich AK, Martin EW Jr, Caligiuri MA, Zheng P, Liu Y.

Blood. 2005 Feb 1;105(3):1114-20. Epub 2004 Oct 14.


On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires.

Sarma S, Bai XF, Liu JQ, May KF Jr, Zheng P, Liu Y.

Cancer Res. 2003 Sep 15;63(18):6051-5.


B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.

Bai XF, Liu J, May KF Jr, Guo Y, Zheng P, Liu Y.

Blood. 2002 Apr 15;99(8):2880-9.


Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.

Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB.

Neoplasia. 1999 Nov;1(5):453-60.


B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion.

Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr, Feng L, Sampsel JW.

Cancer Immunol Immunother. 2000 Jan;48(10):541-9.


Supplemental Content

Support Center